FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In this Phase II study the investigators plan to determine the overall response rate (ORR) of
the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with
liver-only metastatic KRAS wild-type colorectal cancer.